IMPACT-HTN Study of Patients With Hypertension

An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.

NCT Number	NCT07579260
Lead Sponsor	Vivek Bhalla Collaborators: Idorsia Pharmaceuticals Ltd., Duke University Medical Center, Durham, NC
Conditions	Hypertension (HTN), Hypertension, Blood Pressure, High
Enrollment	100 participants
Start Date	2026-07-01
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-29